BioSpace News Archive

- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven Almo at Albert Einstein College of Medicine - Enhances Cue Biopharma’s ability to engineer molecules for therapeutic immune modulation through Immuno-STAT and Neo-STAT platforms CAMBRIDGE, Mass., July 08, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceuti

Dr. Howard Njoo, Canada’s Deputy Chief Public Health Officer, will hold a media technical briefing on data and modelling informing public health action on coronavirus disease.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced today it has completed shipping its Active Pharma Ingredient (API) to both Maryland based Pharmaceutics Int

Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Chris Morabito, M.D., as chief medical officer (CMO). Dr. Morabito joins Cardur

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune res

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a partnership with Takeda Pharmaceutical Company Limited (Takeda) for access to proprietary phage display libraries for the discovery, validation and optimization of antibodies in Takeda’s pipeline of biologics for oncology, rare dis

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that all of the modules for the Defencath™ New Drug Application (NDA) have been submitted to the Food and Drug Administration (FDA). Defencath is being developed as a catheter lock solution with an initial indication for u

Repro Med Systems, Inc. d/b/a KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical”) today announced the appointment of Josh Bennett to the newly created position of Vice President Global Commercialization.

Aptinyx to Host PTSD-Focused R&D Day on August 5 th , 2020 Program to feature presentation from Dr. Murray Stein, Distinguished Professor of Psychiatry at UCSD and board-certified psychiatrist Aptinyx expects data from exploratory Phase 2 study of NYX-783 in PTSD in late 2020 EVANSTON, Ill.--( BUSINESS WIRE )-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of bra

Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense